Vanguard Group Inc. increased its stake in shares of Mallinckrodt PLC (NYSE:MNK) by 0.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,855,030 shares of the company’s stock after buying an additional 610 shares during the period. Vanguard Group Inc. owned about 9.15% of Mallinckrodt PLC worth $598,989,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of MNK. Morris Capital Advisors LLC bought a new position in Mallinckrodt PLC during the first quarter valued at about $234,000. Meeder Asset Management Inc. acquired a new stake in shares of Mallinckrodt PLC during the first quarter valued at $275,000. CENTRAL TRUST Co increased its stake in shares of Mallinckrodt PLC by 15.3% in the second quarter. CENTRAL TRUST Co now owns 4,900 shares of the company’s stock valued at $298,000 after buying an additional 650 shares in the last quarter. Acrospire Investment Management LLC acquired a new stake in shares of Mallinckrodt PLC during the first quarter valued at $300,000. Finally, Algert Global LLC acquired a new stake in shares of Mallinckrodt PLC during the first quarter valued at $324,000. Institutional investors own 94.74% of the company’s stock.
Mallinckrodt PLC (NYSE:MNK) opened at 69.78 on Friday. The firm has a 50-day moving average price of $75.68 and a 200-day moving average price of $66.05. Mallinckrodt PLC has a one year low of $50.90 and a one year high of $85.83. The firm has a market capitalization of $7.52 billion, a P/E ratio of 13.16 and a beta of 1.52.
Mallinckrodt PLC (NYSE:MNK) last released its quarterly earnings results on Tuesday, August 2nd. The company reported $2.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.20. Mallinckrodt PLC had a return on equity of 17.78% and a net margin of 16.39%. The business had revenue of $970.60 million for the quarter, compared to analysts’ expectations of $920.35 million. During the same quarter in the previous year, the firm posted $2.05 earnings per share. The company’s revenue was up .6% compared to the same quarter last year. Equities analysts anticipate that Mallinckrodt PLC will post $7.65 earnings per share for the current year.
MNK has been the subject of several recent analyst reports. Morgan Stanley reissued a “buy” rating and issued a $82.00 price target on shares of Mallinckrodt PLC in a report on Wednesday, September 21st. BMO Capital Markets initiated coverage on Mallinckrodt PLC in a report on Tuesday, June 28th. They issued an “outperform” rating and a $84.00 price target for the company. Mizuho raised their price target on Mallinckrodt PLC from $80.00 to $83.00 and gave the stock a “buy” rating in a report on Thursday, July 21st. Piper Jaffray Cos. raised their price target on Mallinckrodt PLC from $103.00 to $112.00 and gave the stock an “overweight” rating in a report on Wednesday, August 24th. Finally, TheStreet raised Mallinckrodt PLC from a “hold” rating to a “buy” rating in a report on Friday, June 17th. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Mallinckrodt PLC presently has a consensus rating of “Buy” and a consensus price target of $94.54.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.